Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human Remove Human filter Veterinary Remove Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Summaries of opinion Remove Summaries of opinion filter Withdrawn applications Remove Withdrawn applications filter Paediatric investigation plans Remove Paediatric investigation plans filter Referrals Remove Referrals filter Orphan designations (257) Apply Orphan designations filter Direct healthcare professional communication (15) Apply Direct healthcare professional communication filter

Product number

Patient safety

Yes (1) Apply Yes filter

Authorisation status

Authorised (242) Apply Authorised filter Refused (19) Apply Refused filter Withdrawn (26) Apply Withdrawn filter

ATC code

Species

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Opinion status

Negative (1) Apply Negative filter Positive (19) Apply Positive filter

Application type

Initial authorisation (13) Apply Initial authorisation filter Post-authorisation (7) Apply Post-authorisation filter

Withdrawal type

Initial authorisation (52) Apply Initial authorisation filter Post-authorisation (5) Apply Post-authorisation filter

Withdrawal date

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (11) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (87) Apply PM: decision on the application for modification of an agreed PIP filter RPM: decision refers to a refusal on the application for modification of an agreed PIP (1) Apply RPM: decision refers to a refusal on the application for modification of an agreed PIP filter W: decision granting a waiver in all age groups for all conditions or indications (16) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (28) Apply Yes filter

Compliance procedure number

Referral name

Referral status

European Commission final decision (5) Apply European Commission final decision filter

Referral safety status

Yes (1) Apply Yes filter

Referral type

Article 20 procedures (5) Apply Article 20 procedures filter

Referral reference number

Referral decision making model

PRAC-CAT-CHMP-EC (1) Apply PRAC-CAT-CHMP-EC filter PRAC-CHMP-EC (2) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally authorised product(s) (5) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (3) Apply Risk minimisation measures filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Medicine type

Accelerated assessment Remove Accelerated assessment filter Biosimilar Remove Biosimilar filter Orphan medicine Remove Orphan medicine filter Additional monitoring (597) Apply Additional monitoring filter Conditional approval (88) Apply Conditional approval filter Exceptional circumstances (65) Apply Exceptional circumstances filter Generic (354) Apply Generic filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

485 results

Remove all filtersRemove all filters

Categories Human Remove Human filter Veterinary Remove Veterinary filter

Medicine Referrals Remove Referrals filter European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Withdrawn applications Remove Withdrawn applications filter Summaries of opinion Remove Summaries of opinion filter

Medicine type Accelerated assessment Remove Accelerated assessment filter Biosimilar Remove Biosimilar filter Orphan medicine Remove Orphan medicine filter

Sort by

List item

Human medicine European public assessment report (EPAR): Abasaglar (previously Abasria)

insulin glargine, Diabetes Mellitus
Date of authorisation: 09/09/2014, , Revision: 12, Authorised, Last updated: 24/09/2021
List item

Human medicine European public assessment report (EPAR): Abecma

idecabtagene vicleucel, Multiple Myeloma; Neoplasms; Cancer; Neoplasms, Plasma Cell; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Infectious Mononucleosis; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases
Date of authorisation: 18/08/2021, , , , Revision: 6, Authorised, Last updated: 27/07/2023
List item

Human medicine European public assessment report (EPAR): Abevmy

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 21/04/2021, , , Revision: 5, Authorised, Last updated: 15/12/2022
List item

Human medicine European public assessment report (EPAR): Abrysvo (updated)

Respiratory syncytial virus, subgroup A, stabilized prefusion F protein / Respiratory syncytial virus, subgroup B, stabilized prefusion F protein, Respiratory Syncytial Virus Infections
Date of authorisation: 23/08/2023, , , Authorised, Last updated: 26/09/2023
List item

Human medicine European public assessment report (EPAR): Abseamed

epoetin alfa, Anemia; Kidney Failure, Chronic; Cancer
Date of authorisation: 27/08/2007,
Date of refusal: 18/06/2009, , Revision: 22, Authorised, Last updated: 21/08/2023
List item

Human medicine European public assessment report (EPAR): Accofil

filgrastim, Neutropenia
Date of authorisation: 17/09/2014, , Revision: 14, Authorised, Last updated: 24/07/2023
List item

Human medicine European public assessment report (EPAR): Adakveo

Crizanlizumab, Anemia, Sickle Cell
Date of authorisation: 28/10/2020, , , , Revision: 6, Withdrawn, Last updated: 21/08/2023
List item

Human medicine European public assessment report (EPAR): Adcetris

Brentuximab vedotin, Lymphoma, Non-Hodgkin; Hodgkin Disease
Date of authorisation: 25/10/2012, , Revision: 34, Authorised, Last updated: 13/03/2023
List item

Human medicine European public assessment report (EPAR): Alofisel

darvadstrocel, Rectal Fistula
Date of authorisation: 23/03/2018, , , Revision: 10, Authorised, Last updated: 25/05/2023
List item

Human medicine European public assessment report (EPAR): Alpheon

recombinant human interferon alfa-2a, Hepatitis C, Chronic
Date of refusal: 05/09/2006, , Refused, Last updated: 28/06/2006
List item

Human medicine European public assessment report (EPAR): Alprolix

eftrenonacog alfa, Hemophilia B
Date of authorisation: 12/05/2016, , Revision: 8, Authorised, Last updated: 04/11/2021
List item

Human medicine European public assessment report (EPAR): Alsitek

Masitinib mesilate, Amyotrophic Lateral Sclerosis
Date of refusal: 26/07/2018, , Refused, Last updated: 31/07/2018
List item

Human medicine European public assessment report (EPAR): Alymsys

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 26/03/2021, , , Revision: 6, Authorised, Last updated: 26/07/2023
List item

Human medicine European public assessment report (EPAR): Amgevita

adalimumab, Arthritis, Psoriatic; Colitis, Ulcerative; Arthritis, Juvenile Rheumatoid; Spondylitis, Ankylosing; Psoriasis; Crohn Disease; Arthritis, Rheumatoid
Date of authorisation: 21/03/2017, , Revision: 11, Authorised, Last updated: 18/01/2023
List item

Human medicine European public assessment report (EPAR): Amglidia (updated)

glibenclamide, Diabetes Mellitus
Date of authorisation: 24/05/2018, , Revision: 7, Authorised, Last updated: 25/09/2023
List item

Human medicine European public assessment report (EPAR): Amsparity

adalimumab, Arthritis, Rheumatoid; Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing; Uveitis; Hidradenitis Suppurativa; Colitis, Ulcerative; Crohn Disease; Arthritis, Juvenile Rheumatoid
Date of authorisation: 13/02/2020, , , Revision: 4, Authorised, Last updated: 29/10/2021
List item

Human medicine European public assessment report (EPAR): Amvuttra

vutrisiran sodium, Amyloid Neuropathies, Familial
Date of authorisation: 15/09/2022, , , Revision: 1, Authorised, Last updated: 10/01/2023
List item

Human medicine European public assessment report (EPAR): Aplidin

,
Last updated: 26/11/2020
List item

Human medicine European public assessment report (EPAR): Arikayce liposomal

Amikacin sulfate, Respiratory Tract Infections
Date of authorisation: 27/10/2020, , Revision: 2, Authorised, Last updated: 04/08/2023
List item

Human medicine European public assessment report (EPAR): Artesunate Amivas

artesunate, Malaria
Date of authorisation: 22/11/2021, , , Revision: 2, Authorised, Last updated: 23/08/2023
List item

Human medicine European public assessment report (EPAR): Aspaveli

Pegcetacoplan, Hemoglobinuria, Paroxysmal
Date of authorisation: 13/12/2021, , , Revision: 3, Authorised, Last updated: 06/09/2022
List item

Human medicine European public assessment report (EPAR): Aybintio

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 19/08/2020, , , Revision: 7, Authorised, Last updated: 11/04/2023
List item

Human medicine European public assessment report (EPAR): Ayvakyt

Avapritinib, Gastrointestinal Stromal Tumors
Date of authorisation: 24/09/2020, , , , Revision: 7, Authorised, Last updated: 28/06/2023
List item

Human medicine European public assessment report (EPAR): Bekemv

Eculizumab, Hemoglobinuria, Paroxysmal
Date of authorisation: 19/04/2023, , Revision: 1, Authorised, Last updated: 06/07/2023
List item

Human medicine European public assessment report (EPAR): Bemfola

follitropin alfa, Anovulation
Date of authorisation: 26/03/2014, , Revision: 10, Authorised, Last updated: 19/12/2022

Load more

485 results

Human medicine European public assessment report (EPAR): Abasaglar (previously Abasria)

Human medicine European public assessment report (EPAR): Abecma

Human medicine European public assessment report (EPAR): Abevmy

Human medicine European public assessment report (EPAR): Abrysvo (updated)

Human medicine European public assessment report (EPAR): Abseamed

Human medicine European public assessment report (EPAR): Accofil

Human medicine European public assessment report (EPAR): Adakveo

Human medicine European public assessment report (EPAR): Adcetris

Human medicine European public assessment report (EPAR): Alofisel

Human medicine European public assessment report (EPAR): Alpheon

Human medicine European public assessment report (EPAR): Alprolix

Human medicine European public assessment report (EPAR): Alsitek

Human medicine European public assessment report (EPAR): Alymsys

Human medicine European public assessment report (EPAR): Amgevita

Human medicine European public assessment report (EPAR): Amglidia (updated)

Human medicine European public assessment report (EPAR): Amsparity

Human medicine European public assessment report (EPAR): Amvuttra

Human medicine European public assessment report (EPAR): Aplidin

Human medicine European public assessment report (EPAR): Arikayce liposomal

Human medicine European public assessment report (EPAR): Artesunate Amivas

Human medicine European public assessment report (EPAR): Aspaveli

Human medicine European public assessment report (EPAR): Aybintio

Human medicine European public assessment report (EPAR): Ayvakyt

Human medicine European public assessment report (EPAR): Bekemv

Human medicine European public assessment report (EPAR): Bemfola